메뉴 바로가기 본문 바로가기
Tests AlphaLiquid® Solution

The AlphaLiquid® series is a liquid biopsy platform that utilizes the most advanced tumor profiling technology along with Next Generation Sequencing, providing a comprehensive genomic solution for cancer patients.

AlphaLiquid® testing provides in-depth analysis of cancer-related genetic mutations within approximately 2 weeks from receiving the collected blood specimen. The resulting report assists healthcare professionals in making improved clinical decisions for progressive cancer patients.

The test offers a non-invasive and safer approach compared to tissue biopsy, and thus can be repeated whenever necessary. It can be applied for anticancer drug selection, recurrence monitoring, as well as early cancer detection in the near future.

Strengths of AlphaLiquid® Solution
  • 1 Advanced technology in detecting & analyzing tumor DNA from blood
  • 2 Outstanding test performance
  • 3 Large-scale clinical validations
  • 4 Competitive pricing
  • 10+Published journals

  • 6+Patents

  • 10+Partnered medical
    institutions

  • 30+Clinical trials

  • 2000+Clinical samples
    analyzed

  • KFDA IVD
    accreditation pending

Workflow
Sample Collection
  • 20ml whole blood (10mlx2)
  • Sent in Streck™ or AlphaLiquid Tube™ (Room Temp.)
Library prep & NGS
  • Detect ctDNA in blood with patented UniqSeq® technology
  • Perform NGS run
UniqSeq® Analysis
  • SNV, Indel, fusion, CNV, MSI, and TMB data analysis with UniqSeq® analysis pipeline
Clinical Report
  • Offer therapy options
  • Quantitative mutational fraction

10 Days

AlphaLiquid® is a high-precision, comprehensive liquid biopsy solution for advanced solid cancer patients.

With only a single draw of blood, AlphaLiquid® examines mutations in common cancer-related genes. It is designed to facilitate physicians in monitoring progression and changing therapy options.

Recommended for:
  • Patients who are unable to go through invasive tissue biopsy
  • Patients whose tumor tissue cannot be obtained
  • Patients who have not been tested for a long time, or whose tissue biopsy result is outdated
  • Patients with more than one major genetic variations detected from recent biopsy
  • Patients who need more than a single gene test for appropriate diagnosis and/or treatment
QClinical use of AlphaLiquid®
A AlphaLiquid® enables accurate identification and observation of important aspects of cancer that tissue biopsy cannot.

AlphaLiquid® can assist in selecting a more suitable anticancer drug for each patient by tracking how cancer cells evolve over the course of cancer progression. It can also detect trace amount of cancer cells remaining in the blood after treatment, also known as minimal residual disease(MRD), allowing to prepare against possible recurrence.

Tissue biopsy Liquid biopsy
Monitoring treatment response
Early detection of resistance to treatment
Early detection of MRD and recurrence
Tracking cancer cell (clonal) evolution
Early detection of cancer

Source: Heitzer et al. (2019) Nat Rev Genet

QAdvantages of AlphaLiquid®
A
  • 1.Patients can be diagnosed without any bleeding, pain, or complications that are typical of tissue biopsy.
  • 2.Patients can learn the effectiveness of cancer therapy in better detail than any other tests.
  • 3.Early detection of therapy resistance mechanism is possible, thereby maximizing the treatment effects.
  • 4.Provides the fastest way to detect cancer recurrence after surgery.
  • 5.Early diagnosis of cancer is possible.